This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nerves Frayed at Forest

Forest Laboratories (FRX) is entering this quarterly earnings season with a dilemma common to its brand-name peers -- what to do about the threat of generic competition.

The difference is that the impact could be quite uncommon if Forest loses a patent fight for the antidepressant Lexapro, which accounted for $1.87 billion, or 63% of its corporate revenue, for the fiscal year ended March 31.

New York-based Forest is being challenged by Israel's Teva Pharmaceutical Industries (TEVA), which wants to break Lexapro's U.S. patent. A trial was held in March, and a judge's decision is expected this summer, perhaps even this month.

There's plenty of nervousness because Lexapro's impact on Forest is far greater than what, for example, the cholesterol drug Lipitor provides to Pfizer (PFE - Get Report) or the antipsychotic Zyprexa contributes to Eli Lilly (LLY - Get Report).

Shares of those two companies were rattled when generic-drug companies tried to overturn their U.S. patents, but Big Pharma investors rejoiced when Lilly won a court fight in April 2005 and Pfizer prevailed last December.

"We believe the overhang of the [Lexapro] decision will continue to cap the share price," says Robert Uhl of Friedman Billings & Ramsey in a recent research report. Like a majority of analysts, he is neutral on Forest. He doesn't own shares, but his firm says it seeks to do business with companies covered in research reports.

Going to Court

Forest's stock has bounced around from the mid-$30s to the high-$50s, but the net effect over the last 12 months has been basically no change in the shares. The stock closed at $38.56 Wednesday.

The quarter that ended June 30 won't reveal anything about the Lexapro litigation when the results are presented next week, but analysts will certainly ask Forest officials about another event that could affect the drug's sales. Pfizer's antidepressant Zoloft lost U.S. patent protection on June 30, and analysts want to assess the impact of generic versions, especially if managed-care companies persuade their customers to use cheaper products.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FRX $99.00 -0.77%
LLY $83.73 -0.18%
PFE $32.88 2.80%
AAPL $118.05 -0.70%
FB $105.39 -0.33%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.93 -0.21 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs